Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(c)Issuer Purchases of Equity Securities


Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2023 - January 31, 2023	—	(1)	$	—	—	$	2,434,092,348	(2)
February 1, 2023 - February 28, 2023	600,000	(1)	100.933		600,000	2,373,532,278		(2)
March 1, 2023 - March 31, 2023	2,369,830	(1)	101.037		2,369,830	2,134,092,391		(2)
Total	2,969,830	(1)	101.016		2,969,830	$	2,134,092,391	(2)

1.These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

2.On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.

Previous: Item 4. Controls and Procedures · Next: Item 6. Exhibits